BCTXZ

Briacell Therapeutics Corp

• PUBT·1d ago

  BriaCell reports 16.6-month median survival in Phase 2 Bria-IMT breast cancer study

• PUBT·05/15 11:31

  BriaCell adds ovarian cancer immunotherapy candidate Bria-OVA+ to pipeline

• Reuters·05/15 11:30

  BRIACELL EXPANDS PIPELINE TO INCLUDE AN OVARIAN CANCER IMMUNOTHERAPY CANDIDATE, BRIA-OVA+™

• PUBT·05/12 11:30

  BriaCell Phase 3 Bria-IMT breast cancer trial enrollment tops 230 patients

• Reuters·05/12 11:30

  BRIACELL THERAPEUTICS CORP - INTERIM TOPLINE DATA FROM PHASE 3 BRIA-ABC STUDY EXPECTED IN 2026

• PUBT·05/07 11:31

  BriaCell adds NYU Langone Perlmutter as site for Phase 3 breast cancer trial

• Reuters·05/07 11:31

  BRIACELL ADDS NYU LANGONE HEALTH’S PERLMUTTER CANCER CENTER AS CLINICAL SITE IN PIVOTAL PHASE 3 BREAST CANCER STUDY

• PUBT·05/06 11:32

  BriaCell wins FDA clearance to start Bria-BRES+ metastatic breast cancer study

• Reuters·05/06 11:30

  BRIACELL THERAPEUTICS CORP - TO INITIATE PHASE 1/2A STUDY OF BRIA-BRES+ IN COMING MONTHS

• PUBT·04/27 11:30

  BriaCell to present final Phase 2 Bria-IMT survival data at ASCO 2026

• PUBT·04/21 11:31

  BriaCell plans Bria-OTS+ clinical entry in metastatic breast, prostate cancers later this year

• PUBT·04/20 11:31

  BriaCell says Phase 3 Bria-IMT plus checkpoint inhibitor preserves quality of life

• Reuters·03/31 20:07

  BriaPro buys BriaCell soluble CD80 cancer therapy license, BriaCell stake rises to 78%

• Reuters·03/18 11:30

  BriaCell to present four posters at the AACR Annual Meeting